| Enzon Pharmaceuticals, Inc. | ||
 | 685 Route 202/206 | |
| Bridgewater, NJ 08807 | ||
| Phone: | 908 541 8600 | |
| Fax: | 908 575-9457 | |
| www.enzon.com | ||
April 11, 2006
NatImmune A/S
Fruebjergvej 3 box 3
DK-2100 Copenhagen Ø
Denmark
| Re: | Amendment #1 to License Agreement between NatImmune A/S (“NatImmune”) and | |
| Enzon Pharmaceuticals, Inc. (“Enzon”) dated September 30, 2005, as amended by | ||
| Amendment #1 dated November 15, 2005 (the “Agreement”) | ||
Gentlemen:
We are writing to confirm the agreement between NatImmune and Enzon that Section 2.3 of the Agreement concerning the terms for an agreement respecting the Baltic Countries, which provision was amended from “December 31, 2005” to “March 31, 2006” by Amendment #1, be further amended such that “March 31, 2006” be changed to “September 30, 2006”.
All other terms of the Agreement shall remain unchanged. Capitalized words used in this letter that are not defined in this letter shall have the meanings attributed to them in the Agreement.
Please sign below to acknowledge your agreement with the foregoing.
Yours truly,
| ENZON PHARMACEUTICALS, INC. | Accepted and agreed by: | ||
| /s/ Lawrence R. Miller | NATIMMUNE A/S | ||
| Lawrence R. Miller | |||
| Vice President and General Counsel | By: | /s/ Martin Bonde | |
| Name: Martin Bonde | |||
| Title: Chief Executive Officer | |||
| By: | /s/ Claus Berner Møller | ||
| Name: Claus Berner Møller | |||
| Title: Chairman | |||